Dextrose with Calcium, Magnesium and Sodium Electrolytes

Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, and Sodium Lactate Overview

When patients develop severe chronic kidney disease or end-stage renal disease, their kidneys lose the ability to filter metabolic waste products, regulate fluid balance, and maintain electrolyte homeostasis. The intraperitoneal solution combining Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, and Sodium Lactate widely known under the brand name Dianeal is an essential peritoneal dialysis fluid. Utilized extensively in nephrology and general medicine, this specialized sterile fluid is instilled directly into the peritoneal cavity to perform continuous or automated peritoneal dialysis.

What Is This Peritoneal Dialysis Solution and How Does It Work?

This intraperitoneal solution is a sterile, non-pyrogenic fluid engineered to facilitate transperitoneal transport of solutes and water. During peritoneal dialysis, the fluid is instilled into the peritoneal cavity via an indwelling catheter, where it remains for a specified dwell time. Dextrose functions as the osmotic agent, creating a hyperosmular gradient across the peritoneal membrane that draws excess water from the blood vessels into the abdominal fluid (ultrafiltration).

Is This Peritoneal Dialysis Solution FDA Approved?

Yes, this multi-component peritoneal dialysis solution is fully FDA approved. It received its initial regulatory approval in (September 1978) and remains a core therapy for home-based and hospital-based renal replacement therapy worldwide.

What Is This Peritoneal Dialysis Solution Used For?

• End-Stage Renal Disease (ESRD): Prescribed for chronic maintenance peritoneal dialysis in patients with end-stage renal disease when kidney function has permanently failed.
• Acute Kidney Injury: Utilized in select clinical settings for acute peritoneal dialysis to manage severe fluid overload, hyperkalemia, or acute uremic syndrome.
• Refractory Fluid Overload: Used to remove excess fluid in severe, treatment-resistant congestive heart failure or volume overload under nephrology supervision.

Before Taking This Solution: Contraindications & Precautions

Because this solution is instilled directly into the abdominal cavity, it alters intra-abdominal pressure and interacts continuously with the peritoneal membrane. Before initiating peritoneal dialysis, nephrologists must thoroughly evaluate the patient’s abdominal anatomy, respiratory capacity, and infection risks. Patients with structural abdominal defects or severe scarring may experience inadequate dialysis or severe physical complications. In addition, because the solution contains dextrose, diabetic patients require close blood glucose monitoring to prevent severe hyperglycemia.

Who Should Not Take This Solution?

• Patients with uncorrectable mechanical defects in the abdominal wall, diaphragm, or abdominal cavity (such as unrepaired hernias) that increase the risk of fluid leakage or respiratory compromise.
• Individuals with extensive abdominal adhesions, previous major abdominal surgeries, or severe peritoneal scarring that significantly reduces effective peritoneal surface area.
• Patients with severe lactic acidosis, as the lactate component may worsen systemic lactate buildup if liver metabolism is severely impaired.

Pregnancy & Fertility

Animal reproduction studies have not been conducted with this specific intraperitoneal solution. Managing end-stage renal disease during pregnancy is complex and carries high risks for both mother and fetus. Peritoneal dialysis can be continued during pregnancy, but intra-abdominal dwell volumes are typically reduced to prevent excessive intra-abdominal pressure, pre-term labor, or respiratory compromise.

Tell Your Doctor Before Using This Solution

Complete medical transparency is essential when starting peritoneal dialysis. Patients must inform their nephrologist if they have a history of severe abdominal hernia, inflammatory bowel disease, chronic liver disease, or frequent abdominal infections. Diabetic patients must explicitly discuss their glucose control, as significant amounts of dextrose absorb systemically from the peritoneal cavity during each dwell.

Dosage & Administration

The dosing strategy for peritoneal dialysis solutions is highly individual and prescribed as a complete dialysis regimen by a nephrologist. Regimens are tailored based on the patient’s body size, residual kidney function, peritoneal membrane transport characteristics, and fluid clearance targets. Dosing involves selecting specific dextrose concentrations (1.5 percent, 2.5 percent, or 4.25 percent) and specifying exchange volumes, dwell times, and the total number of daily exchanges.

Standard Dosing Guidelines

• Continuous Ambulatory Peritoneal Dialysis (CAPD): Typically involves 3 to 5 manual exchanges per day, with dwell times ranging from 4 to 8 hours and fill volumes of 1.5 to 2.5 liters per exchange.
• Automated Peritoneal Dialysis (APD): Performed overnight using an automated cycler machine delivering multiple short-dwell exchanges over 8 to 10 hours, often combined with a daytime dwell.
• Dextrose Selection: Higher dextrose concentrations (2.5 percent or 4.25 percent) yield greater osmotic fluid removal (ultrafiltration) and are selected when greater fluid removal is needed.

How This Solution Is Administered

• Administered strictly into the peritoneal cavity through an surgically implanted, permanent indwelling peritoneal dialysis catheter (such as a Tenckhoff catheter).
• Must be warmed to body temperature (37 degrees Celsius or 98.6 degrees Fahrenheit) prior to infusion using dry heat warmers; microwave heating must never be used due to risk of uneven heating and tissue burns.
• Rigorous aseptic technique must be maintained during every connection and disconnection to prevent bacterial contamination of the peritoneal cavity.

Clinical Efficacy & Research

Decades of global clinical experience and extensive nephrology research establish this dextrose-based peritoneal dialysis solution as a cornerstone of home renal replacement therapy. Clinical studies demonstrate that regular peritoneal dialysis exchanges with balanced electrolyte solutions effectively maintain metabolic control, clear uremic toxins, and manage volume overload in patients with end-stage renal disease.

Side Effects & Safety Profile

Intraperitoneal administration of dialysis fluid alters intra-abdominal pressure and introduces large amounts of glucose into the abdominal cavity. While necessary for life-sustaining renal replacement, continuous exposure to high-dextrose fluids can lead to localized and metabolic side effects. Furthermore, the presence of an indwelling abdominal catheter creates a permanent portal of entry for potential infectious pathogens, requiring constant vigilance by the patient and healthcare team.

Common Side Effects (>10%)

• Abdominal discomfort, feeling of fullness, or mild bloating due to increased intra-abdominal pressure during fluid dwells.
• Hyperglycemia (elevated blood sugar) and weight gain resulting from systemic absorption of dextrose across the peritoneal membrane.
• Mild electrolyte shifts, including changes in serum sodium, potassium, or calcium levels.

Serious Adverse Events

• Peritonitis (severe infection of the peritoneal membrane), presenting as cloudy effluent fluid, severe abdominal pain, fever, and nausea.
• Severe fluid overload or dehydration resulting from improper selection of dextrose concentration strength.
• Encapsulating peritoneal sclerosis (EPS), a rare but life-threatening long-term complication involving severe peritoneal membrane thickening and bowel obstruction.

Managing Side Effects

If effluent fluid appears cloudy or if abdominal pain develops, the patient must immediately contact their peritoneal dialysis nurse or nephrologist and save the drained bag for laboratory analysis. To manage dextrose-induced weight gain and hyperglycemia, dietitians adjust calorie intake and physicians modify insulin regimens. Catheter site care must be performed daily using antiseptic techniques to prevent exit-site and tunnel infections.

Drug Interactions & What to Avoid

Because peritoneal dialysis actively clears water-soluble substances from the bloodstream and alters body fluid volumes, it significantly impacts the pharmacokinetics of concurrent medications. Dialyzable drugs may be removed during fluid dwells, requiring timing adjustments or supplemental dosing.

Drug-Drug Interactions

• Digitalis Glycosides (Digoxin): Rapid removal of potassium or calcium shifts during dialysis increases the risk of severe digoxin toxicity and fatal cardiac dysrhythmias.
• Insulin: Systemic absorption of dextrose from the peritoneal solution increases blood glucose levels, often requiring higher doses of subcutaneous or intraperitoneal insulin in diabetic patients.
• Antihypertensive Medications: Significant fluid removal during ultrafiltration can cause sudden blood pressure drops; blood pressure drugs may need to be withheld prior to exchanges.

Food & Alcohol

Dietary management is a central component of peritoneal dialysis. Patients must follow specific nutritional guidelines provided by a renal dietitian. While peritoneal dialysis removes potassium and phosphorus better than standard hemodialysis, dietary control of sodium and fluid intake remains necessary to prevent volume overload. Alcohol consumption should be strictly limited or avoided, as alcohol alters liver metabolism, worsens fluid retention, and can interact with medications taken for chronic kidney disease.

Missed Dose, Overdose & Storage

Peritoneal dialysis relies on a continuous, scheduled daily regimen. Skipping exchanges leads to accumulation of fluid and lethal uremic toxins. Overdose in peritoneal dialysis manifests as fluid overload or severe metabolic disturbances due to incorrect fluid selection or excessive dwell times.

Missed Dose

If a scheduled manual exchange is missed, it should be performed as soon as possible. If using an automated cycler overnight and a session is interrupted, contact your dialysis clinic for specific instructions. Do not attempt to double the fill volume in a single exchange to make up for a missed cycle, as excessive intra-abdominal volume can cause severe pain, hernia, or respiratory distress.

Overdose & Emergency

An overdose can occur if an excessive volume is infused, if an incorrect (too high) dextrose concentration is used continuously, or if fluid is allowed to remain in the abdomen for too long without draining. Symptoms include severe abdominal distension, shortness of breath, profound dehydration, severe hyperglycemia, or blood pressure spikes. Emergency treatment involves immediate drainage of the peritoneal fluid, assessment of vital signs, and corrective intravenous fluid or electrolyte therapy under direct nephrology care.

Storage Instructions

Store solution bags at controlled room temperature between 20 degrees Celsius and 25 degrees Celsius (68 degrees Fahrenheit to 77 degrees Fahrenheit). Brief exposure to temperatures up to 40 degrees Celsius (104 degrees Fahrenheit) is permitted. Keep bags inside their protective overwrap until ready for use to prevent moisture loss. Protect from excessive heat and do not freeze. Inspect bags visually before use; do not use if the fluid is cloudy, discolored, or if leakages are detected.

Patient Management & Monitoring

Safe and effective peritoneal dialysis requires rigorous routine clinical monitoring. Because patients perform exchanges at home, continuous education and regular outpatient clinical evaluations ensure that dialysis adequacy goals are met and complications are prevented.

Tests Before Starting Treatment

• Comprehensive metabolic panel (serum creatinine, blood urea nitrogen, sodium, potassium, calcium, magnesium, phosphate, and albumin).
• Baseline blood glucose and hemoglobin A1c testing, particularly in diabetic patients.
• Peritoneal Equilibration Test (PET) performed a few weeks after starting therapy to determine individual peritoneal membrane transport characteristics.

Monitoring During Treatment

• Regular monthly blood tests to assess dialysis adequacy (Kt/V urea clearance), serum electrolytes, hemoglobin, and nutritional markers.
• Daily self-monitoring of body weight, blood pressure, temperature, and fluid balance (ultrafiltration totals).
• Routine inspection of drained dialysate fluid for clarity and daily assessment of the catheter exit site for signs of infection.

Do’s and Don’ts

• DO perform all exchanges in a clean, quiet room with windows closed and pets excluded to maintain sterility.
• DO wear a surgical mask and wash hands thoroughly before handling the catheter or fluid bags.
• DON’T use microwave ovens to heat fluid bags; always use an approved dry-heat warming pouch or cycler machine heater.
• DON’T proceed with an exchange if the drained fluid appears cloudy, yellow-green, or contains floating specks; contact your clinic immediately.

Frequently Asked Questions

References

• U.S. FDA Label Information for Dianeal Peritoneal Dialysis Solutions (Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, Sodium Lactate).
• U.S. FDA Drugs@FDA – Application Number: 020163, Initial Approval Date: September 1978.

Legal Disclaimer

This educational document is intended for informational purposes only and does not substitute for formal medical advice, clinical diagnosis, or specialized treatment. Always consult a qualified nephrologist, peritoneal dialysis nurse, or healthcare provider with specific questions regarding kidney disease, peritoneal dialysis regimens, or prescription drug administration.